The U.S. Food and Drug Administration has approved a new cholesterol pill from Merck, marking the arrival of a different type of treatment in the market. The drug, called Lipfendra, is described as a PCSK9 inhibitor taken in pill form.
The approval is notable because the medicine works differently from statins, the long-established class of drugs commonly used to manage cholesterol. That distinction could draw attention from patients and clinicians looking at new options for cholesterol care.
Merck announced the FDA decision on Thursday, underscoring the significance of a regulatory green light for a product in a major area of cardiovascular treatment. A pill version of a PCSK9 inhibitor also stands out because it brings a newer mechanism into an oral format.
The development adds to the range of prescription therapies aimed at lowering cholesterol and reflects continued innovation in heart health treatment. More details about how Lipfendra will be used in practice are expected to shape how the newly approved drug fits alongside existing therapies.
